
PRDA optimistic about 2024 dividend increase
19 Feb 2025 10:12
Weak performance, PRDA remains optimistic for dividend allocation. Here's what the CEO has to say.
19 Feb 2025 10:12
Weak performance, PRDA remains optimistic for dividend allocation. Here's what the CEO has to say.
19 Feb 2025 08:41
Prodia readies its subsidiary, Proline, to debut on the stock market in the next 2-3 years.
01 Nov 2024 14:58
PT Prodia Widyahusada Tbk (PRDA), the company that oversees the Prodia laboratory network, is still experiencing a downward trend in net profit until September 2024.
28 Jun 2024 12:51
PT Prodia Widyahusada Tbk (PRDA) takes an extra measure to secure supply chain of in vitro diagnostic (IVD) test tools by acquiring 39% of its affiliate, PT Prodia Diagnostic Line (Proline).
25 Jun 2024 15:07
PT Prodia Diagnostic Line (Proline), "sister company" of PT Prodia Widyahusada Tbk (PRDA) which is engaged in manufacturing reagents and test equipment, has just held the topping off of its newest production facility building today (25/6) in the Jababeka area, Cikarang.
18 Apr 2024 16:06
PT Prodia Widyahusada Tbk (PRDA) has prepared moderate amount of capital expenditure (capex) in 2024, worth a maximum of IDR 250 billion.
18 Apr 2024 11:14
PT Prodia Widyahusada Tbk (PRDA), a company managing Prodia laboratory network, has allocated IDR 155.6 billion to be distributed to its shareholders as cash dividend.
11 Dec 2023 13:55
PT Prodia StemCell Indonesia (ProSTEM), sister company of PT Prodia Widyahusada Tbk (PRDA), officially inaugurates Advanced Cell Therapy-Production Laboratory (ACT-PLab) phase one today (11/12) in Kramat, not far from Prodia headquarter at Prodia Tower.
27 Sep 2023 18:11
PT Prodia Widyahusada Tbk (PRDA) encourages investment in the healthcare sector whilst opening up for any investment opportunities in the future.
13 Apr 2023 11:23
PT Prodia Widyahusada Tbk (PRDA) has consistently distributed dividends in the 2022 fiscal year of IDR 237.9 per share, despite recording a decline in revenue and profit due to normalization after the COVID-19 pandemic.